Brian P. Hobbs, Ph.D.
Affiliations: | 2010 | Biostatistics | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Biostatistics Biology, Statistics, Public HealthGoogle:
"Brian Hobbs"Cross-listing: PHTree
Parents
Sign in to add mentor| Bradley P. Carlin | grad student | 2010 | UMN | |
| (Bayesian hierarchical modeling for adaptive incorporation of historical information in clinical trials.) | ||||
Collaborators
Sign in to add collaborator| Clifton David Fuller | collaborator | UT MD Anderson Cancer Center (MPROTree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shah C, Hobbs BP, Vicini F, et al. (2020) The Diminishing Impact of Margin Definitions and Width on Local Recurrence Rates following Breast-Conserving Therapy for Early-Stage Invasive Cancer: A Meta-Analysis. Annals of Surgical Oncology |
| Pestana RC, Sen S, Hobbs BP, et al. (2020) Histology-agnostic drug development - considering issues beyond the tissue. Nature Reviews. Clinical Oncology |
| Statler AB, Wei W, Gupta A, et al. (2020) Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis. Clinical Breast Cancer |
| Lin SH, Hobbs BP, Verma V, et al. (2020) Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902503 |
| Ahluwalia MS, Peereboom DM, Ciolfi M, et al. (2020) Phase II study of pembrolizumab plus SurVaxM for glioblastoma at first recurrence. Journal of Clinical Oncology. 38: TPS2581-TPS2581 |
| Sussman TA, Wei W, Hobbs B, et al. (2020) A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness. Journal of Clinical Oncology. 38 |
| Ornstein MC, Zabell J, Wood LS, et al. (2020) A phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 38: 5021-5021 |
| Statler AB, Hobbs BP, Wei W, et al. (2019) Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis. Scientific Reports. 9: 18126 |
| Moreno AC, Fellman B, Hobbs BP, et al. (2019) Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Ornstein MC, Wood LS, Hobbs BP, et al. (2019) A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. Journal For Immunotherapy of Cancer. 7: 127 |